List of Excipients in Branded Drug LEVITRA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
GlaxoSmithKline LLC	LEVITRA	vardenafil hydrochloride	0173-0829	CELLULOSE, MICROCRYSTALLINE
GlaxoSmithKline LLC	LEVITRA	vardenafil hydrochloride	0173-0829	CROSPOVIDONE
GlaxoSmithKline LLC	LEVITRA	vardenafil hydrochloride	0173-0829	FERRIC OXIDE RED
GlaxoSmithKline LLC	LEVITRA	vardenafil hydrochloride	0173-0829	FERRIC OXIDE YELLOW
GlaxoSmithKline LLC	LEVITRA	vardenafil hydrochloride	0173-0829	HYPROMELLOSE
GlaxoSmithKline LLC	LEVITRA	vardenafil hydrochloride	0173-0829	MAGNESIUM STEARATE
GlaxoSmithKline LLC	LEVITRA	vardenafil hydrochloride	0173-0829	POLYETHYLENE GLYCOL

Levitra Excipient Strategy and Commercial Opportunities for Vardenafil

Last updated: August 1, 2026

Levitra’s commercial opportunity is now centered on generic vardenafil, differentiated oral delivery, and formulation improvements rather than the original brand. The immediate opportunity is a low-cost, standard immediate-release tablet. Higher-value opportunities include orally disintegrating tablets, taste-masked formulations, lower-dose products, and fixed-dose or on-demand combinations. The core formulation uses conventional excipients, which lowers manufacturing barriers but also limits protection from formulation competitors.

What is Levitra and which formulation does it use?

Levitra is the former Bayer and GlaxoSmithKline brand for vardenafil hydrochloride, a phosphodiesterase-5 inhibitor used to treat erectile dysfunction. The FDA approved Levitra tablets in 2003 under NDA 021400. The marketed strengths were 2.5 mg, 5 mg, 10 mg, and 20 mg [1].

Vardenafil is administered orally and is formulated as an immediate-release film-coated tablet. The product is intended for use approximately 25 to 60 minutes before sexual activity. Food, particularly a high-fat meal, can reduce the rate of absorption, although the FDA label does not require complete fasting [1].

The original tablet has a conventional excipient profile:

Formulation component	Likely function
Microcrystalline cellulose	Diluent and tablet-structure former
Crospovidone	Superdisintegrant
Colloidal silicon dioxide	Glidant and flow aid
Magnesium stearate	Lubricant
Hypromellose	Film-coating polymer
Titanium dioxide	Opacifier and colorant
Ferric oxide pigments	Tablet-color control
Triacetin	Film-coating plasticizer

The active pharmaceutical ingredient is vardenafil hydrochloride trihydrate. The formulation relies on direct-compression or closely related conventional tableting technology. It does not require a complex controlled-release system, lipid vehicle, biologic stabilizer, or specialized device.

What excipients are used in Levitra tablets?

The principal commercial excipients are standard oral solid-dose materials with broad regulatory acceptance. Their availability supports generic entry and reduces supply-chain risk.

Microcrystalline cellulose

Microcrystalline cellulose provides bulk and compressibility. It is particularly useful for low-dose drugs such as vardenafil because the active ingredient represents a small fraction of tablet mass. Selection of particle size and grade affects blend uniformity, tablet hardness, disintegration, and compression speed.

A generic manufacturer can use equivalent microcrystalline cellulose grades from multiple suppliers. This weakens supplier exclusivity but creates opportunities for excipient companies offering improved flow, low-moisture grades, or co-processed cellulose systems.

Crospovidone

Crospovidone accelerates tablet breakup and supports rapid dissolution. For an on-demand erectile-dysfunction product, rapid disintegration has direct commercial value because patients expect a predictable onset.

Crospovidone level, particle size, and intra-granular versus extra-granular addition can materially affect dissolution. A formulation using more efficient disintegration may permit smaller tablets or lower quantities of other excipients.

Colloidal silicon dioxide

Colloidal silicon dioxide improves powder flow and reduces segregation risk. This is important because the dosage strength is low and content uniformity is a key manufacturing attribute.

Overuse can impair compression or alter dissolution. The commercial opportunity is limited for the standalone ingredient, but co-processed excipient systems may improve blend uniformity and reduce process variability.

Magnesium stearate

Magnesium stearate provides lubrication during compression and ejection. Excessive mixing can create hydrophobic coating around particles and slow dissolution. Generic developers must control lubricant concentration and blending time through process validation.

Film-coating excipients

The film coat controls appearance, swallowability, tablet identification, and limited moisture protection. Hypromellose-based coatings are widely available and offer low regulatory risk. Pigment selection creates modest opportunities for brand differentiation but generally does not create meaningful intellectual-property protection.

What was the Levitra orally disintegrating formulation?

Staxyn was an orally disintegrating tablet version of vardenafil. It was marketed as a 10 mg tablet that disintegrated on the tongue without water. The product used a different excipient strategy from conventional Levitra tablets.

Staxyn’s inactive ingredients included mannitol, microcrystalline cellulose, crospovidone, colloidal silicon dioxide, magnesium stearate, aspartame, and flavoring materials, according to the product labeling [2].

Attribute	Levitra conventional tablet	Staxyn orally disintegrating tablet
Dosage form	Film-coated tablet	Orally disintegrating tablet
Water required	Generally yes	No
Main diluent	Microcrystalline cellulose	Mannitol and microcrystalline cellulose
Taste management	Conventional coating	Flavor and sweetener system
Patient differentiation	Limited	Convenience and portability
Manufacturing complexity	Low to moderate	Moderate to high
Formulation risk	Dissolution and content uniformity	Taste, friability, moisture, disintegration

The Staxyn platform illustrates the strongest excipient-led opportunity for vardenafil. The value does not come from the active ingredient alone. It comes from rapid oral disintegration, acceptable mouthfeel, taste masking, moisture control, and mechanical strength.

What formulation patents protect Levitra and Staxyn?

The original Levitra product was protected by compound and formulation-related patent rights, including U.S. Patent No. 6,362,178, which covered vardenafil-related compounds and had an expiration date in the early 2020s after patent-term adjustment. Other listed patents and pediatric-exclusivity periods affected the timing of generic approval and launch [3][4].

The relevant protection categories included:

1. Vardenafil chemical-composition claims.
2. Pharmaceutical-composition claims.
3. Treatment claims for erectile dysfunction.
4. Orally disintegrating and rapidly dissolving formulations.
5. Manufacturing and solid-dosage-form claims.

The strongest commercial barriers were compound and composition claims. Conventional excipient combinations, such as microcrystalline cellulose, crospovidone, silicon dioxide, and magnesium stearate, are difficult to protect broadly because they are widely used in oral tablets.

A new formulation could still obtain patent protection if it demonstrates a specific technical effect, such as:

• Faster disintegration at a defined hardness.
• Improved vardenafil stability under humidity stress.
• Reduced bitterness without delaying dissolution.
• Improved bioavailability under fed conditions.
• Lower tablet mass at equivalent exposure.
• A defined particle-size distribution or solid-state form.
• A novel taste-masking matrix.
• A specific excipient ratio linked to measurable performance.

Broad claims covering “vardenafil with conventional pharmaceutical excipients” would face substantial validity and freedom-to-operate risks.

When did Levitra lose exclusivity?

Levitra’s principal U.S. small-molecule exclusivity has expired. Generic vardenafil tablets entered the U.S. market after FDA approval of abbreviated new drug applications, and the brand no longer controls the market through active regulatory exclusivity.

The main commercial chronology is:

Event	Date
FDA approval of Levitra	August 2003
FDA approval of Staxyn	2010
Key Levitra patent period	Extended into the early 2020s in the United States
Generic vardenafil approvals	Began in the late 2010s
Current market position	Generic-dominated; brand availability limited

Generic launch timing depended on patent litigation, Paragraph IV certifications, and settlement terms. ANDA applicants could challenge listed patents by certifying that the patents were invalid, unenforceable, or would not be infringed. The commercial significance of those challenges has diminished as the relevant patent terms have expired.

What is the Orange Book status of Levitra?

The FDA Orange Book historically listed Levitra under NDA 021400 and included patent information associated with the drug product. Orange Book status should be assessed by product strength, dosage form, and current listing status because patents may expire, delist, or become legally irrelevant after the relevant term ends [3].

For current commercial planning, the key distinction is between:

• Expired compound or formulation patents.
• Any residual listed method-of-use patents.
• Patent-term adjustment.
• Pediatric exclusivity.
• ANDA approval dates and any applicable exclusivity.
• Whether a generic is approved for all strengths or only selected strengths.

Method-of-use patents have weaker practical value when the product’s labeled use is broad and generic substitution is already established. They can still affect certification strategy and labeling, but they rarely recreate the commercial position of an expired erectile-dysfunction product.

Which companies are challenging or competing with Levitra?

The principal competition comes from generic manufacturers of vardenafil tablets rather than from a single branded challenger. Generic competition includes manufacturers operating through ANDA filings, contract manufacturers, and regional pharmaceutical companies.

The broader therapeutic competition includes:

Product	Active ingredient	Dosage form	Commercial position
Viagra and generic sildenafil	Sildenafil citrate	Tablets, some chewable products	Largest established PDE5 competitor
Cialis and generic tadalafil	Tadalafil	Tablets	Longer duration and daily-use positioning
Levitra and generic vardenafil	Vardenafil HCl	Tablets	On-demand PDE5 product
Stendra and generic avanafil	Avanafil	Tablets	Newer PDE5 entrant with rapid-onset positioning

Vardenafil competes primarily on perceived onset, efficacy, tolerability, and price. Tadalafil has a formulation and commercial advantage in daily dosing because of its longer half-life. Sildenafil has the broadest generic familiarity. Vardenafil’s strongest differentiation opportunity is therefore a convenient oral delivery format rather than a conventional tablet.

What excipient strategy creates the best commercial opportunity?

The most attractive strategy is a layered formulation program:

Low-risk generic tablet

A conventional immediate-release tablet can use widely accepted excipients and established manufacturing equipment. This approach minimizes development time, validation cost, and regulatory risk.

The product should target:

• Rapid dissolution.
• Robust content uniformity at 2.5 mg and 5 mg strengths.
• Low tablet weight.
• Stable supply of excipients.
• Multiple qualified sources for each critical material.

The limitation is low pricing power. A standard tablet is readily substitutable and difficult to differentiate.

Orally disintegrating tablet

An ODT can command a higher price if it provides reliable waterless administration, acceptable taste, and adequate mechanical strength. Mannitol is attractive because it provides a cooling mouthfeel and compressibility. Crospovidone supports fast disintegration, while flavors and sweeteners address bitterness.

Critical quality attributes include:

• Disintegration time.
• Wetting time.
• Tablet friability.
• Mechanical strength.
• Mouthfeel.
• Vardenafil uniformity.
• Dissolution after oral disintegration.
• Stability under humidity exposure.

The major risk is that the excipient system may improve mouthfeel while slowing dissolution or increasing moisture sensitivity.

Taste-masked tablet or mini-tablet

A taste-masked product could target patients who dislike swallowing conventional tablets. Polymer coating, ion-exchange resins, cyclodextrins, lipid barriers, and multiparticulate systems are possible approaches.

Taste masking must avoid delaying vardenafil release. A formulation patent is more defensible when it links a defined taste-masking composition to a specified dissolution profile and pharmacokinetic result.

Fast-dissolving film

An oral film could provide portability and waterless dosing. It would require low-dose uniformity, rapid dissolution, adequate film strength, controlled moisture uptake, and effective taste masking.

The technical barrier is higher than for an ODT. Vardenafil’s bitter taste and low-dose content-uniformity requirements create formulation challenges. A film may be commercially attractive in selected markets but requires stronger packaging and process controls.

Combination products

A vardenafil combination with another erectile-dysfunction agent is unlikely to be commercially attractive because of overlapping mechanisms, safety concerns, and regulatory complexity. Combinations with non-PDE5 agents could be more differentiated but would require clinical evidence and careful cardiovascular risk assessment.

How strong is the patent estate for a new vardenafil formulation?

The legacy Levitra patent estate is commercially weak after expiration of the principal compound and formulation rights. A new developer could obtain meaningful protection only through a technically specific formulation or manufacturing invention.

Patent strategy	Relative strength	Commercial assessment
Conventional tablet with standard excipients	Low	Easy to design around
New vardenafil salt or solid form	Moderate to high	Requires solid-state and stability differentiation
ODT with defined excipient ratios	Moderate	Stronger if linked to performance data
Taste-masked formulation	Moderate	Depends on claim breadth and clinical relevance
Oral film	Moderate	Higher technical barrier, but more process risk
New indication or dosing regimen	Moderate	Requires enforceable method-of-use claims
Manufacturing process	Moderate	Useful if difficult to replicate and detectable

Patent applicants should avoid relying solely on excipient identity. The stronger approach combines composition, process, dissolution, stability, and pharmacokinetic claims.

What FDA regulatory pathway applies to vardenafil products?

A conventional generic vardenafil tablet is generally pursued through an ANDA under section 505(j) of the Federal Food, Drug, and Cosmetic Act. The applicant must demonstrate pharmaceutical equivalence and bioequivalence to the reference listed drug.

A materially different dosage form, such as an oral film or a product with a distinct route or delivery mechanism, may require a 505(b)(2) application. The pathway depends on the proposed formulation, reference product, clinical data package, and extent of reliance on prior FDA findings.

Key regulatory considerations include:

• Bioequivalence across strengths.
• Dissolution profile matching.
• Food-effect assessment where required.
• Vardenafil content uniformity.
• Impurity and degradation-product control.
• Stability under International Council for Harmonisation conditions.
• Excipient safety and prior oral use.
• Labeling differences for ODT, film, or taste-masked products.
• Packaging protection against moisture and light.

Aspartame-containing products must address phenylalanine labeling requirements. Flavor systems and novel excipients can increase regulatory review time.

What manufacturing and IP barriers affect commercial entry?

The manufacturing barrier for a conventional Levitra-equivalent tablet is low. Standard tablet presses, film coaters, blending equipment, and high-shear or dry-granulation systems are widely available.

Higher barriers apply to ODT and film products:

• Low-dose blend uniformity.
• Moisture-sensitive excipient systems.
• Controlled porosity.
• Taste-masking reproducibility.
• Mechanical strength after packaging.
• Rapid disintegration without excessive friability.
• Specialized blister packaging.
• Scale-up without changing dissolution.

The strongest manufacturing-related intellectual property would protect a process that produces a defined particle distribution, tablet structure, or release profile. Process patents are more valuable when competitors cannot easily detect or reproduce the process from the finished dosage form.

What revenue exposure remains for Levitra?

The original branded revenue base has been eroded by generic entry and competition from sildenafil and tadalafil. Bayer reported Levitra as part of its prescription pharmaceutical portfolio before the product’s commercial decline, but current revenue attributable to the brand is limited relative to the product’s peak period [5].

The remaining revenue opportunities are concentrated in:

1. Authorized generic or regional generic supply.
2. Private-label vardenafil.
3. ODT and waterless-dosing products.
4. Specialty-market licensing.
5. Contract manufacturing.
6. Formulation-technology licensing.
7. Combination or differentiated delivery products.

A conventional generic strategy is volume-driven. An ODT, oral film, or taste-masked product can support higher gross margins but requires stronger evidence of patient preference and better protection against rapid copycat entry.

Key Takeaways

• Levitra is an immediate-release vardenafil hydrochloride tablet built around conventional excipients.
• The principal excipients are microcrystalline cellulose, crospovidone, colloidal silicon dioxide, magnesium stearate, and film-coating materials.
• Staxyn demonstrates the most relevant differentiated excipient strategy: mannitol-based oral disintegration combined with flavoring, sweetening, and taste control.
• Levitra’s principal compound and formulation exclusivity has expired, leaving a generic-dominated market.
• A conventional vardenafil tablet has low formulation and patent barriers.
• ODTs, oral films, taste-masked tablets, and novel solid forms offer stronger commercial differentiation.
• New patent claims should connect excipient composition to dissolution, taste, stability, bioavailability, or manufacturing performance.
• Generic vardenafil tablets generally follow the ANDA pathway; materially different delivery systems may require 505(b)(2) development.
• The best near-term opportunity is a differentiated, moisture-stable, taste-masked ODT with rapid disintegration and reliable bioequivalence.

FAQs

Is vardenafil still commercially available after Levitra?

Yes. Vardenafil remains available primarily through generic products, although brand Levitra availability has declined substantially.

Which excipient improves Levitra tablet disintegration?

Crospovidone is the principal superdisintegrant used in the conventional tablet formulation. Its level and manufacturing placement affect dissolution and disintegration.

Can a generic manufacturer copy Levitra’s excipients?

A generic manufacturer can use equivalent excipients and must meet pharmaceutical-equivalence and bioequivalence requirements. It does not need to duplicate every excipient grade or manufacturing parameter.

Is Staxyn a generic Levitra product?

Staxyn is a distinct orally disintegrating vardenafil product rather than a conventional Levitra tablet. Its formulation uses a different excipient and taste-management strategy.

What is the best patent opportunity for a new vardenafil product?

The strongest opportunity is a narrowly defined delivery or formulation technology supported by data showing improved disintegration, taste, stability, bioavailability, or patient-use characteristics.

References

1. U.S. Food and Drug Administration. (2003). Levitra (vardenafil hydrochloride) tablets prescribing information. Bayer Pharmaceuticals Corporation.

2. U.S. Food and Drug Administration. (2010). Staxyn (vardenafil hydrochloride) orally disintegrating tablets prescribing information. Bayer HealthCare Pharmaceuticals.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

4. U.S. Patent and Trademark Office. (2024). Patent Center and patent-term information. https://patentcenter.uspto.gov/

5. Bayer AG. (2010). Annual report 2009. Bayer AG.